OverviewSuggest Edit

Akero Therapeutics develops medicines that restore metabolic balance to treat non-alcoholic steatohepatitis (NASH) and other serious metabolic diseases. Akero's lead clinical program, AKR-001, is a long-acting Fc fusion modified FGF21 protein and potential treatment for NASH. AKR-001 builds upon two decades of work on FGF21 biology. It is designed to affect both the liver and adipose tissue, reducing liver fat and suppressing inflammation and fibrosis.
TypePublic
Founded2017
HQSan Francisco, CA, US
Websiteakerotx.com

Latest Updates

Employees (est.) (Mar 2020)13(+63%)
Share Price (Sept 2021)$23.7
Cybersecurity ratingAMore

Key People/Management at Akero Therapeutics

Jonathan Young

Jonathan Young

Chief Operating Officer & Co-Founder
Tim Rolph

Tim Rolph

Chief Science Officer & Co-Founder
William White

William White

Chief Financial Officer & Head of Corporate Development
Andrew Cheng

Andrew Cheng

President & Chief Executive Officer, Director
Kitty Yale

Kitty Yale

Chief Development Officer
Arin Bose

Arin Bose

Vice President for Drug Substance Process Development
Show more

Akero Therapeutics Office Locations

Akero Therapeutics has offices in San Francisco, Cambridge and South San Francisco
San Francisco, CA, US (HQ)
170 Harbor Way 3rd Floor
Cambridge, MA, US
400 Technology Square, 400 Technology Square 10th Floor
South San Francisco, CA, US
601 Gateway Blvd #350
Show all (3)

Akero Therapeutics Financials and Metrics

Akero Therapeutics Revenue

USD

Net income (Q1, 2021)

(15.1m)

EBIT (Q1, 2021)

(15.1m)

Market capitalization (6-Sept-2021)

826.6m

Closing stock price (6-Sept-2021)

23.7

Cash (31-Mar-2021)

188.0m

EV

640.1m
Akero Therapeutics's current market capitalization is $826.6 m.
Annual
USDFY, 2017FY, 2018FY, 2019FY, 2020

General and administrative expense

1.1m1.9m8.6m15.2m

R&D expense

3.5m11.9m37.0m64.9m

Operating expense total

4.6m13.8m45.7m80.2m

EBIT

(4.6m)(13.8m)(45.7m)(80.2m)
Quarterly
USDQ3, 2019Q1, 2020Q2, 2020Q1, 2021

General and administrative expense

2.4m3.6m3.4m4.5m

R&D expense

13.9m8.8m13.0m10.6m

Operating expense total

16.3m12.4m16.5m15.1m

EBIT

(16.3m)(12.4m)(16.5m)(15.1m)
Annual
USDFY, 2017FY, 2018FY, 2019FY, 2020

Cash

598.0k76.0m64.8m187.2m

Prepaid Expenses

40.0k1.2m1.6m3.0m

Current Assets

638.0k77.1m138.0m271.3m

PP&E

131.0k
Quarterly
USDQ3, 2019Q1, 2020Q2, 2020Q1, 2021

Cash

147.8m47.2m63.2m188.0m

Prepaid Expenses

2.2m933.0k10.4m5.8m

Current Assets

150.1m126.2m113.2m255.8m

PP&E

120.0k
Annual
USDFY, 2017FY, 2018FY, 2019FY, 2020

Net Income

(4.6m)(81.7m)(43.8m)(79.2m)

Depreciation and Amortization

17.0k

Accounts Payable

60.0k1.3m(426.0k)2.5m

Cash From Operating Activities

(4.4m)(4.6m)(35.6m)(70.8m)
Quarterly
USDQ3, 2019Q1, 2020Q2, 2020Q1, 2021

Net Income

(28.1m)(11.9m)(28.1m)(15.1m)

Depreciation and Amortization

11.0k

Accounts Payable

(1.3m)588.0k1.6m1.2m

Cash From Operating Activities

(24.0m)(11.3m)(33.9m)(18.3m)
USDFY, 2017

Financial Leverage

1.5 x
Show all financial metrics

Akero Therapeutics Acquisitions / Subsidiaries

Company NameDateDeal Size
Akero Securities Corporation

Akero Therapeutics Cybersecurity Score

Cybersecurity ratingPremium dataset

A

96/100

SecurityScorecard logo

Akero Therapeutics Online and Social Media Presence

Embed Graph

Akero Therapeutics News and Updates

Akero Therapeutics to Present at the Morgan Stanley Virtual Global Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a cardio-metabolic biotechnology company developing transformational treatments for non-alcoholic steatohepatitis (NASH), today announced that members of the management team will present at the…

Akero Therapeutics Reports Second Quarter 2021 Financial Results and Provides Business Update

SOUTH SAN FRANCISCO, Calif., Aug. 13, 2021 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a cardio-metabolic biotechnology company developing transformational treatments for non-alcoholic steatohepatitis (NASH), today reported second quarter financial results for the period ending Ju…

Akero Therapeutics Appoints Judy Chou, Ph.D., to its Board of Directors

SOUTH SAN FRANCISCO, Calif., July 14, 2021 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a cardio-metabolic biotechnology company developing transformational treatments for non-alcoholic steatohepatitis (NASH), today announced the appointment of Judy Chou, Ph.D., to its board of dir…

Akero Therapeutics Presents at the American Diabetes Association’s 81st Scientific Sessions, Demonstrating that Improvements in Adipose Tissue Metabolism Contributed Substantially to Improved Liver Health and Better Glycemic Control in Efruxifermin (EFX)-treated Pre-Cirrhotic NASH Patients

SOUTH SAN FRANCISCO, Calif., June 25, 2021 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a cardio-metabolic biotechnology company developing transformational treatments for non-alcoholic steatohepatitis (NASH), today announced additional analyses from its Phase 2a BALANCED study of …

Akero Therapeutics Presents Analyses at the 2021 International Liver Congress Showing Normalization of Liver Fat Substantially Reduced Markers of Liver Injury and Fibrosis, and Greatly Increased Probability of Resolving NASH

Analyses also Show that Combining a Threshold for ALT Reduction of ≥17 U/L with Normalization of Liver Fat Improves Predictive Power for Resolution of NASH with 1-Stage Improvement of Fibrosis Analyses also Show that Combining a Threshold for ALT Reduction of ≥17 U/L with Normalization of Liver Fat …

Akero Therapeutics to Present Efruxifermin (EFX) Results Showing Histologic Improvement in EFX-Treated F4 Cirrhotic Patients as a Late-Breaker Oral Presentation at the 2021 International Liver Congress

This Month, Akero Will Present Three Abstracts at EASL and Two Abstracts at the 81st Meeting of the American Diabetes Association (ADA) This Month, Akero Will Present Three Abstracts at EASL and Two Abstracts at the 81st Meeting of the American Diabetes Association (ADA)
Show more

Akero Therapeutics Blogs

Efruxifermin is Associated With Improved Glucose Metabolism in Patients With NASH and Type 2 Diabetes

Frias, J. et al. (2021) ADA Scientific Sessions The post Efruxifermin is Associated With Improved Glucose Metabolism in Patients With NASH and Type 2 Diabetes first appeared on Akero.

Increased adiponectin following efruxifermin treatment is associatedwith improvements in dyslipidemia, glucose metabolism, and liver health in a 16-week, randomized, placebo-controlled trial in NASH

Frias, J. et al. (2021) ADA Scientific Sessions The post Increased adiponectin following efruxifermin treatment is associatedwith improvements in dyslipidemia, glucose metabolism, and liver health in a 16-week, randomized, placebo-controlled trial in NASH first appeared on Akero.

Correlation between changes in liver fat content and improvements in serum markers of liver injury, fibrosis, and metabolism, and in histologic parameters following treatment with efruxifermin

Harrison, S. et al. (2021) EASL The post Correlation between changes in liver fat content and improvements in serum markers of liver injury, fibrosis, and metabolism, and in histologic parameters following treatment with efruxifermin first appeared on Akero.

The role of reduction in liver fat content (MRI-PDFF) and ALT in predicting treatment response in NASH: A secondary analysis of the randomized, controlled BALANCED trial

Loomba, R. et al. (2021) EASL The post The role of reduction in liver fat content (MRI-PDFF) and ALT in predicting treatment response in NASH: A secondary analysis of the randomized, controlled BALANCED trial first appeared on Akero.
Show more

Akero Therapeutics Frequently Asked Questions

  • When was Akero Therapeutics founded?

    Akero Therapeutics was founded in 2017.

  • Who are Akero Therapeutics key executives?

    Akero Therapeutics's key executives are Jonathan Young, Tim Rolph and William White.

  • How many employees does Akero Therapeutics have?

    Akero Therapeutics has 13 employees.

  • Who are Akero Therapeutics competitors?

    Competitors of Akero Therapeutics include Surya Dermato Medica Laboratories, Corassist Cardiovascular and Fairfax Cryobank.

  • Where is Akero Therapeutics headquarters?

    Akero Therapeutics headquarters is located at 170 Harbor Way 3rd Floor, San Francisco.

  • Where are Akero Therapeutics offices?

    Akero Therapeutics has offices in San Francisco, Cambridge and South San Francisco.

  • How many offices does Akero Therapeutics have?

    Akero Therapeutics has 3 offices.